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sation was higher in females (F: 30 vs. M: 15 %, p = 0.01). 
after adjustment for baseline characteristics, complete re-
vascularisation (0.84; 95 % ci 0.54–1.32) and gender (1.11; 
95 % CI 0.73–1.69)  lost  significance. Also  the gender-by-












plete revascularisation) are factors known to affect mor-
tality  in  patients  with  ST-elevation  myocardial  infarction 
(steMi) and multivessel disease [1–3]. evidence of a 
higher mortality  in  females  dates  back  to  the  fibrinolysis 
era [4], particularly in patients presenting with STEMI (20 




in women presenting with steMi to higher age and more 
comorbidity  at  presentation  or  to  less  effective  treatment 
and fewer drug-eluting stents [7, 10]. Others found gender 
to be an independent predictor for mortality [11].
Currently, the optimal revascularisation strategy for mul-
tivessel disease is a matter of debate [3, 12] and the impact 
Abstract
Background gender and complete revascularisation are 
known to affect mortality. The objective of this study was 
to analyse a gender difference in mortality with respect to 
complete revascularisation for multivessel disease after 
primary percutaneous coronary intervention (PPCI) in ST-
elevation myocardial infarction (STEMI) patients.
Method in a prospective consecutive cohort of 1472 pa-
tients  presenting with  STEMI  for  PPCI,  between  January 
2006 and January 2010, 832 patients with multivessel dis-
ease were  analysed. The  primary  outcome was  long-term 
mortality.
Results Median follow-up was 3.3 ± 1.2 years. Complete re-
vascularisation was performed less in females than in males 
(30 vs. 38 %; p = 0.04). at PPci, women (27 %, n = 221) 
were ± 10  years  older  (p = 0.001),  had more hypertension, 
renal failure and symptoms of heart failure (all p < 0.01). cu-
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of  gender  has  not  been  investigated  yet.  Therefore,  the 
objective of this study was to investigate long-term mortal-
ity  in  relation  to  complete  revascularisation  for multives-





From  January  2006  to  January  2010,  1472  consecu-
tive  patients  were  prospectively  registered with  PPCI  for 
steMi [13, 14], of whom 997 (50 %) had multivessel dis-
ease. according to local protocol, all patients with multives-
sel disease, except for patients with multivessel Pci (7 %), 
were adjudicated for revascularisation strategy by the ‘heart 
team’ (93 %, at least one interventional cardiologist and one 
heart  surgeon). Multivessel disease was defined as > 50 % 




Patients with  prior  coronary  artery  bypass  graft  (CABG), 
cardiogenic shock, an intra-aortic balloon pump, mechani-
cal ventilation or resuscitation at presentation for PPci were 
excluded (n = 165; 17 %). as presented in Fig. 1, the remain-
ing 832 (56 %) patients with multivessel disease were ana-
lysed  according  to  gender  and  revascularisation  strategy: 
incomplete  revascularisation,  in  which  only  the  culprit 
lesion was treated at PPci versus complete revascularisa-
tion  of  all  significant  non-culprit  lesions  during  the  PPCI 
procedure  or  in  a  staged  session  (PCI:  median;  18  days, 
IQR:  12–40  days  or CABG: median;  16  days,  IQR  8–46 
days).
Clinical variables
Hospital records and angiographic images were reviewed 
for procedural data and clinical variables including age, 
gender,  smoking  habit,  use  of  medication  or  history  of 
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ation and skewed data as median with interquartile range 
(IQR)  25th−75th  percentile.  Data  are  censored  at  end  of 
life or end of follow-up (September 2012). Crude mortality 
was analysed by  the Kaplan-Meier method using  the  log-
rank  test. Logistic  regression was used for  the analysis of 
in-hospital mortality. Proportional Cox regression analysis 
was utilised for 1-year and  long-term mortality  in women 




acteristics were added  to gender and  treatment strategy  in 
the multivariate analysis according to a maximum of 10 % 
of the number of in-hospital events (1 event; age), at 1-year 
(4  events;  age,  time  to  first medical  contact,  renal  failure 
at admission (gFr < 0.30 ml/mmol), procedural success) 
and  in  the  long-term  (7  events;  age,  time  to  first medical 
contact, renal failure at admission (gFr < 0.30 ml/mmol), 
procedural  success,  previous  acute  myocardial  infarction, 




all tests were two-sided, a p-value < 0.05 was considered 
statistically  significant.  Statistical  analysis was  performed 
using sPss statistical software for Windows.
Results
as presented in table 1,  women were  significantly  older 
(71.2 ± 12.1 vs. 61.8 ± 12.3, p < 0.001), more often had 
hypertension, symptoms of heart failure and renal failure at 
admission than men (all p < 0.01). smoking, familial predis-
position, and previous Pci were more frequent in men (all 
p < 0.05). Previous STEMI and median time from symptom 
to first medical contact was comparable between genders. 
complete revascularisation for multivessel disease was 
more frequent in men than in women (38 vs. 30 %, p = 0.04). 
there was an equal distribution of two- and three-vessel 
disease, culprit and non-culprit  lesions. During PPCI, gly-
coprotein iib-iiia inhibitors were more often used in males 
than in females (62 vs.72 %, p = 0.005). No significant gen-
der difference was shown for TIMI flow pre- or post-PPCI, 
the number of stents placed and the stent length. However, 
the diameter of the stent was smaller in females than in 
males (3.01 vs. 3.15 mm, p = 0.002).
Mortality
as presented in Fig. 2, in-hospital mortality was similar in 
men and women (M: 2 vs. F: 3 %, p = 0.27). in the long-
filtration rate  (GFR) < 30 ml/min) at the time of presenta-




ulation  registry  (‘Statistics  Netherlands’)  in  The  Hague. 
Follow-up was achieved in hospital in 100 % and during 
follow-up in 99 %, as only 1 % of patients migrated.
Medical treatment from ambulance to catheterisation 
laboratory
All patients presenting within 6 h from the onset of symp-
toms with steMi received a loading dose of clopidogrel 
600 mg orally, acetylsalicylic acid (250 mg intravenously or 
300 mg orally) and 5000 IU heparin at first medical contact 
(either  in  the  ambulance  or  at  the  emergency  room). The 
use of glycoprotein IIb-IIIA inhibitors and/or low-molecu-
lar-weight heparin before, during or after PPci was at the 





After  PPCI,  clopidogrel  75  mg/day  was  maintained  for 
at  least  12  months  and  acetylsalicylic  acid  80  mg/day 










Quantitative data are expressed as mean ± sD and nominal 
data  as  frequencies  followed by percentages  (n; %). Data 
were  checked  for  a  normal  distribution  and  analysed  by 
either the independent sample t-test or chi-square test when 
applicable. Nominal data were analysed using a Chi-square 
test or a Mann-Whitney U test when appropriate. Data with 
a normal distribution are presented as mean ± standard devi-
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in lower cumulative mortality than incomplete revasculari-
sation (in-hospital: 1 vs. 3 %, p = 0.009, at 1-year: 2 vs. 6 %, 
p = 0.007 and long term: 7 vs. 10 %, p = 0.08).
term,  cumulative mortality  was  higher  in  women  than  in 
men (at 1 year: 8 vs. 4 %, p = 0.009 and at long-term: 13 vs. 
7 %, p = 0.004). Overall, complete revascularisation resulted 
Baseline characteristics N (%) Female (n = 221; 27 %) Male (n = 611; 73 %) P
age (mean ± sD) 71.2 ± 12.1 61.8 ± 12.3 0.001
Diabetes mellitus 46 (21) 128 (21) ns
Hypercholesterolaemia 54 (24) 126 (21) ns
History renal failure 7 (3) 17 (3) ns
Hypertension 111 (50) 223 (37) < 0.001
Family history 66 (30) 233 (38) 0.03
smoker 71 (32) 259 (42) 0.008
Symptoms of heart failure 15 (7) 16 (3) 0.005
Previous percutaneous coronary intervention 10 (5) 53 (9) 0.046
Previous acute myocardial infarction 17 (8) 47 (8) ns
gFr < 0.30 ml/mmol at presentation 58 (29) 80 (14) < 0.001
Procedural characteristics n (%)
Median; 25th–75th percentile
Symptom-first medical contact (hours) 1:42.(1:00–4:00) 1:33 (0:45–3:06) 0.08
First medical contact-needle (hours) 0:35.(0:10–1:13) 0:30 (0:10–1:15) 0.40
needle-balloon (hours) 0:15 (0:11–0:21) 0:16 (0:11–0:22) 0.52
incomplete revascularisation 154(70) 378 (62) 0.04
complete revascularisation after PPci 67 (30) 233 (38)
1-stage Pci 11 (4) 50 (8) ns
2-stage Pci 28 (13) 95 (16) ns
CABG 28 (13) 88 (14) ns
three-vessel disease 114 (51) 294 (48) ns
culprit
left anterior descending 87 (39) 219 (36) ns
Right coronary artery 100 (45) 262 (43) ns
Left circumflex 32 (15) 123 (21) ns
left main 1 (1) 0 (0) ns
non-culprit
left anterior descending 109 (49) 329 (54) ns
Right coronary artery 84 (38) 224 (37) ns
Left circumflex 133(60) 343 (56) ns
left main 35 (6) 18 (8) ns
Glycoprotein IIb/IIIa inhibitor 133 (62) 432 (72) 0.005
TIMI-flow pre-primary percutaneous intervention
0 141 (64) 435 (71) ns
1 33 (15) 68 (11)
2 32 (15) 78 (13)
3 15 (7) 30 (5)
TIMI-flow post- primary percutaneous intervention
0 5 (2) 6 (1) ns
1 7 (3) 8 (1)
2 17 (8) 53 (9)
3 192 (87) 544 (89)
Procedural success 185 (84) 521(85) ns
Drug-eluting stent 86 (40) 196 (32) ns
Bare metal stent 132 (60) 411 (68) 0.04
total number of stents 1.45 ± 0.91 1.46 ± 0.83 ns
Diameter stents 3.01 ± 0.51 3.15 ± 0.52 0.002
length of stent 19.9 ± 7.8 20.7 ± 8.3 ns
Table 1 Baseline and procedural characteristics of ST-elevation myocardial infarct patients with multi-vessel disease at primary percutaneous 
intervention
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Mortality in females vs. males according to age
A  significant  gender  disparity  in  age  at  presentation  for 





as presented in table 3, complete revascularisation had 
lower  mortality  than  incomplete  revascularisation  during 
follow-up, however not in hospital. Females had higher 
mortality than males at 1-year and also in the long term. The 
interaction  of  complete  revascularisation-by-gender  and 
age-by-gender  was  not  significant  (p = 0.73). the interac-
Mortality in females vs. males according to treatment 
strategy
as shown in table 2,  in women  no  significant  difference 
for mortality was  shown between complete or  incomplete 
revascularisation during follow-up, whereas in men a sig-
nificantly lower mortality was shown for complete revascu-
larisation in hospital (p < 0.001).
Mortality in females vs. males according to treatment 
strategy
as presented in Fig. 3, complete revascularisation had higher 
in-hospital mortality in females than in males (p = 0.005), but 







complete revascularisation (cr) incomplete revascularisation (icr) icr vs. cr 
in females
icr vs. cr 
in males









in-hospital 5 % (3) 0 % (1) 0.005 3 % (4) 3 % (10) 0.65 0.46 < 0.001
1-year 5 % (3) 1 % (3) 0.11 9 % (19) 5 % (14) 0.05 0.24 0.02
long-term 9 % (6) 6 % (14) 0.32 15 % (23) 8 % (30) 0.01 0.23 0.30
Fig. 2 Long-term mortality  in male and  female patients with multi-
vessel disease after primary PCI for ST-elevation myocardial  infarc-
tion. A significantly higher mortality in women was shown at 1-year, 
*p = 0.009 and at long term, **p=0.004
 
Fig. 3 Mortality according to treatment strategy in females and males. 
Kaplan-Meier:  in  the  long  term women benefit more  from complete 
than from incomplete revascularisation, at 1 year*, p = 0.05 and at long 
term **, p = 0.01; CR complete revascularisation, ICR incomplete re-
vascularisation, ♂ male, ♀ female
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term. However, when mortality was analysed between gen-
ders according to age, a significantly higher mortality was 
shown in females compared with males under the age of 60 
years, independent of risk profile.
this is an important topic because recent literature has 
shown better clinical outcome with complete revasculari-
sation in patients with multivessel disease [3]. this is also 
underlined  by  the  Culprit  study,  with  a  lower  rate  of  the 
composite endpoint in patients with complete revascularisa-
tion (Hr: 0.45; 95 % ci: 0.24–0.84; p = 0.009) [15]; how-
ever, no significance was shown for mortality. Our analysis 
shows an overall lower mortality with complete revasculari-
sation. However, complete revascularisation was performed 
significantly less often in women than in men, whereas no 
significant  difference was  shown  for  three-vessel  disease, 
culprit or non-culprit lesions. in addition, incomplete revas-
cularisation had higher long-term mortality in females than 
in males. Previous research has shown less aggressive man-
agement strategies with lower frequencies of Pci and less 
aggressive medical treatment in women [16, 17]. Women in 
our analysis had smaller vessels and more often renal failure 
at admission and this might have complicated a complete 
revascularisation strategy. According to Gevaert et al. [18] 
renal failure at admission is an independent predictor for 
in-hospital mortality, however with similar impact between 
genders.
The  unadjusted  mortality  was  higher  in  women  dur-
ing  follow-up,  but  reduced  significantly  after  adjustment 
for risk profile. This is  in accordance with recent research 
[1, 19–21], and underlines the importance of aggressive 








in the long term only (p = 0.03 and p = 0.002, respectively).
Multivariate analysis
as shown in table 3, after adjustment for baseline charac-
teristics gender no longer predicted mortality and complete 
revascularisation was only associated with 1-year morality. 
The interaction for age under 60 years-by-gender (p = 0.006) 








cance was lost after adjustment for baseline characteristics. 
In  addition,  the  gender-by-complete  revascularisation  and 
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Conclusion
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